IMU Stock Overview
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.17 |
| 52 Week High | US$6.67 |
| 52 Week Low | US$3.05 |
| Beta | 1.06 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 2.16% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 41.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 0.6% |
| 1Y | 2.2% | -23.7% | 5.4% |
Return vs Industry: IMU exceeded the German Biotechs industry which returned -23.4% over the past year.
Return vs Market: IMU underperformed the German Market which returned 4.7% over the past year.
Price Volatility
| IMU volatility | |
|---|---|
| IMU Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IMU has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMU's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 106 | Mark Enyedy | www.immunogen.com |
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| IMU fundamental statistics | |
|---|---|
| Market cap | €1.06b |
| Earnings (TTM) | -€193.57m |
| Revenue (TTM) | €92.03m |
11.6x
P/S Ratio-5.5x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMU income statement (TTM) | |
|---|---|
| Revenue | US$95.61m |
| Cost of Revenue | US$203.85m |
| Gross Profit | -US$108.25m |
| Other Expenses | US$92.85m |
| Earnings | -US$201.09m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.91 |
| Gross Margin | -113.22% |
| Net Profit Margin | -210.33% |
| Debt/Equity Ratio | 0% |
How did IMU perform over the long term?
See historical performance and comparison